Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of “Hold” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $52.00.

Several brokerages recently commented on OMCL. Wells Fargo & Company lifted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Bank of America reiterated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th.

Insiders Place Their Bets

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.64% of the stock is currently owned by company insiders.

Institutional Trading of Omnicell

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares in the last quarter. 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the period. Headlands Technologies LLC bought a new position in shares of Omnicell during the second quarter valued at approximately $104,000. Summit Global Investments bought a new position in shares of Omnicell during the third quarter valued at approximately $221,000. Finally, QRG Capital Management Inc. purchased a new position in shares of Omnicell during the third quarter valued at approximately $231,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of Omnicell stock opened at $45.32 on Friday. Omnicell has a one year low of $25.12 and a one year high of $55.74. The business’s 50 day simple moving average is $46.17 and its two-hundred day simple moving average is $40.47. The stock has a market capitalization of $2.10 billion, a P/E ratio of -116.20, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.